IRIDEX (NASDAQ:IRIX) Major Shareholder Shih-Yao David Lin Buys 20,000 Shares of Company Stock

IRIDEX Corporation (NASDAQ:IRIX) major shareholder Shih-Yao David Lin bought 20,000 shares of the company’s stock in a transaction on Friday, July 18th. The stock was bought at an average price of $1.28 per share, with a total value of $25,600.00. Following the completion of the acquisition, the insider owned 705,461 shares in the company, valued at $902,990.08. This represents a 2.92% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

IRIDEX Stock Up 29.4%

Shares of IRIX opened at $0.88 on Thursday. IRIDEX Corporation has a 52-week low of $0.61 and a 52-week high of $1.65. The stock has a fifty day simple moving average of $0.73 and a two-hundred day simple moving average of $0.95. The company has a market capitalization of $15.46 million, a PE ratio of -4.40 and a beta of 0.67.

IRIDEX (NASDAQ:IRIX) last announced its quarterly earnings results on Tuesday, August 18th. The medical equipment provider reported ($0.07) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.06). The firm had revenue of $12.57 million for the quarter, compared to analysts’ expectations of $13.59 million. As a group, equities analysts anticipate that IRIDEX Corporation will post -0.12 earnings per share for the current fiscal year.

Trending Headlines about IRIDEX

Here are the key news stories impacting IRIDEX this week:

• Positive Sentiment: SEC disclosures show Lin made dozens of purchases totaling substantial share amounts, including transactions of 50,000 shares at $0.99, 40,114 shares at $1.00 and 80,000 shares at $1.00. The repeated buying and growing ownership stake may be interpreted as a sign of confidence in IRIDEX’s long-term prospects. IRIDEX major shareholder buys 50,000 shares
• Positive Sentiment: The filings also include purchases at prices ranging from approximately $0.84 to $1.52, with several individual transactions valued between roughly $20,000 and $58,000. This broad pattern of buying, rather than a single isolated trade, likely attracted speculative interest in the thinly traded stock. IRIDEX major shareholder acquires stock
• Neutral Sentiment: Investors should note that most purchases occurred weeks or months earlier, from March through June and in prior reporting periods; the disclosures are new, but the buying itself is not. The reports therefore provide sentiment support rather than evidence of a new operating development or immediate improvement in revenue and earnings.
• Neutral Sentiment: Trading in IRIX was temporarily halted under a Limit Up-Limit Down (LULD) pause, indicating that the stock’s rapid move exceeded permitted price bands. This highlights significant volatility and the potential for sharp reversals once trading resumes.

Wall Street Analyst Weigh In

Separately, Weiss Ratings upgraded shares of IRIDEX from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, October 2nd. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $3.00.

Institutional Investors Weigh In On IRIDEX

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. United Capital Financial Advisors LLC purchased a new stake in IRIDEX in the second quarter valued at $41,000. Bank of New York Mellon Corp purchased a new position in shares of IRIDEX during the 2nd quarter worth $29,000. Weber Capital Management LLC ADV purchased a new position in shares of IRIDEX during the 2nd quarter worth $206,616. Diversify Advisory Services LLC acquired a new stake in shares of IRIDEX during the 2nd quarter worth about $30,000. Finally, Renaissance Technologies LLC increased its position in shares of IRIDEX by 6.7% during the 1st quarter. Renaissance Technologies LLC now owns 396,627 shares of the medical equipment provider’s stock worth $401,000 after purchasing an additional 25,067 shares during the last quarter. Institutional investors and hedge funds own 20.10% of the company’s stock.

IRIDEX Company Profile

IRIDEX Corporation (NASDAQ: IRIX) develops and sells ophthalmic laser systems and related delivery devices used in the treatment of eye diseases. Its products are designed primarily for ophthalmologists treating glaucoma and retinal disorders, including diabetic retinopathy and other conditions affecting the retina.

The company’s portfolio includes laser systems such as the Cyclo G6 glaucoma laser platform and the IQ series of retinal photocoagulation lasers. IRIDEX also offers specialized probes and other delivery devices, including MicroPulse and transscleral cyclophotocoagulation technologies, which are intended to provide targeted treatment while limiting exposure to surrounding tissue.

Founded in 1989 and headquartered in Mountain View, California, IRIDEX serves eye-care professionals through a combination of direct sales and distributor relationships in the United States and international markets.